Vanda Pharmaceuticals (VNDA)
(Real Time Quote from BATS)
$4.16 USD
-0.05 (-1.19%)
Updated Aug 6, 2025 12:42 PM ET
4-Sell of 5 4
B Value F Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Vanda Pharmaceuticals Inc. has a PEG ratio of 0.56 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.14.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VNDA 4.16 -0.05(-1.19%)
Will VNDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VNDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VNDA
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
VNDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Surges 6.0%: Is This an Indication of Further Gains?
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Other News for VNDA
Vanda Pharmaceuticals Inc (VNDA) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Rising ...
Q2 2025 Vanda Pharmaceuticals Inc Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Projects Cash Holdings of $280M-$320M by End of 2025
Vanda Pharmaceuticals (VNDA) Reports Lower Q2 Revenue than Expected
Vanda Pharmaceuticals reports Q2 EPS (46c) vs. (8c) last year